Date: 2017-10-31
Type of information: Nomination
Compound: chief medical officer
Company: Basilea Pharmaceutica (Switzerland)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 31, 2017, Basilea Pharmaceutica reported that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea's Head of Development, to succeed Prof. Kaufhold in the role of chief medical officer and as a member of the management committee effective January 1, 2018.
- Dr. Engelhardt joined Basilea in 2010 as head of clinical research. In 2012, he was promoted to head of sevelopment. In this role Dr. Engelhardt led Basilea's clinical research and development group, and acted as Prof. Kaufhold's deputy. Prior to joining Basilea, Dr. Engelhardt served as global program medical director at Novartis Pharma AG in Basel, before which he held various positions with increasing responsibility at Bracco-Altana, Konstanz, Germany and Bracco Diagnostics in Princeton, NJ, USA.
- Dr. Engelhardt holds a medical degree and a PhD from the University Frankfurt/Main, Germany and is board certified in internal medicine.
Financial terms:
Latest news:
Is general: Yes
